SecBot SecBot
SECBOTREPLAY Home › Report › VTGN

VTGN · Vistagen announced that its fasedienol clinical program has exceeded…

Vistagen Therapeutics, Inc. · 8-K filed Jun 9, 2026 at 17:04 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jun 9, 2026 at 17:04 ET

Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, with over 1,500 subjects receiving at least one dose, over 300 with at least 6 months of exposure, and over 100 with at least 12 months. This is a regulatory milestone for the NDA pathway, but the company has not yet aligned with the FDA on specific requirements. Topline results from the pivotal PALISADE-4 Phase 3 trial are expected in Q2 2026, and from the Phase 2 repeat dose study in Q3 2026.

  • Fasedienol program exceeded ICH E1 minimum safety exposure recommendations as of May 31, 2026
  • Over 1,500 subjects received at least a single exposure to fasedienol
  • Over 300 subjects with at least 6 months of exposure
  • Over 100 subjects with at least 12 months of exposure

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access